Eisai Co., Ltd., commonly referred to as Eisai, is a prominent global pharmaceutical company headquartered in Japan. Established in 1941, Eisai has made significant strides in the healthcare industry, focusing on the discovery, development, and marketing of innovative medicines. With major operational regions across Asia, Europe, and North America, the company is dedicated to addressing unmet medical needs, particularly in neurology and oncology. Eisai's core products include treatments for Alzheimer's disease and various cancers, distinguished by their commitment to patient-centric solutions. The company has achieved notable recognition for its research and development efforts, positioning itself as a leader in the pharmaceutical sector. With a strong emphasis on ethical practices and collaboration, Eisai continues to enhance its market presence while striving to improve the quality of life for patients worldwide.
How does Eisai's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Eisai's score of 62 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Eisai Co., Ltd., headquartered in Japan, reported total greenhouse gas emissions of approximately 585,860,000 kg CO2e. This figure includes 48,586,000 kg CO2e from Scope 1 emissions, 2,673,000 kg CO2e from Scope 2 emissions, and a significant 563,928,000 kg CO2e from Scope 3 emissions, primarily from purchased goods and services. Eisai has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 55% by fiscal 2030, using fiscal 2019 as the base year. Additionally, the company targets a 27.5% reduction in Scope 3 emissions within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to achieving net-zero emissions by 2050. In previous years, Eisai's emissions have shown fluctuations, with 2022 emissions recorded at approximately 602,655,000 kg CO2e, and 2021 emissions at about 521,809,000 kg CO2e. The company is actively working towards its reduction goals, with progress monitored against its established targets.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Eisai's Scope 3 emissions, which decreased by 6% last year and increased by approximately 24% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" representing nearly all of their reported Scope 3 footprint.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Eisai has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Eisai's sustainability data and climate commitments